<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Hepatol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Hepatol Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Current Hepatology Reports</journal-title></journal-title-group><issn pub-type="epub">2195-9595</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10075503</article-id><article-id pub-id-type="pmcid-ver">PMC10075503.1</article-id><article-id pub-id-type="pmcaid">10075503</article-id><article-id pub-id-type="pmcaiid">10075503</article-id><article-id pub-id-type="pmid">37214274</article-id><article-id pub-id-type="doi">10.1007/s11901-023-00601-y</article-id><article-id pub-id-type="publisher-id">601</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Portal Hypertension in Alcohol-Associated Hepatitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>McConnell</surname><given-names initials="MJ">Matthew J.</given-names></name><address><email>matthew.mcconnell@yale.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8032-5654</contrib-id><name name-style="western"><surname>Iwakiri</surname><given-names initials="Y">Yasuko</given-names></name><address><email>yasuko.iwakiri@yale.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000000419368710</institution-id><institution>Section of Digestive Diseases, Department of Internal Medicine, </institution><institution>Yale School of Medicine, </institution></institution-wrap>1080 LMP, 333 Cedar Street, New Haven, CT 06520 USA </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year>2023</year></pub-date><volume>22</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">432785</issue-id><fpage>67</fpage><lpage>73</lpage><history><date date-type="accepted"><day>23</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>06</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-29 08:25:09.593"><day>29</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="11901_2023_Article_601.pdf"/><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">This review article will examine portal hypertension in alcoholic hepatitis (AH) from both a basic mechanistic and a clinical perspective.</p></sec><sec><title>Recent Findings</title><p id="Par2">Alcoholic hepatitis is a major public health problem in the USA, accounting for over 300,000 hospital admissions in a recent year of data (Jinjuvadia et al. J Clin Gastroenterol.&#160;<xref ref-type="bibr" rid="CR60">60</xref>;49:506&#8211;511). Portal hypertension is a key consequence of AH and a driver of liver-related morbidity and mortality. Alcohol may directly mediate portal hypertension via multiple possible mechanisms, including increased portal inflow, increased intrahepatic vasoconstriction, inflammation, and changes in the liver vasculature such as perisinusoidal fibrosis and phlebosclerosis.</p></sec><sec><title>Summary</title><p id="Par3">Portal hypertension is a key consequence of AH and a critical area for future research.
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Liver sinusoidal endothelial cell</kwd><kwd>Endotheliopathy</kwd><kwd>Alcohol-associated liver disease</kwd><kwd>Alcohol-associated liver cirrhosis</kwd><kwd>Nitric oxide</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>R01DK117597</award-id><principal-award-recipient><name name-style="western"><surname>Iwakiri</surname><given-names>Yasuko</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000027</institution-id><institution>National Institute on Alcohol Abuse and Alcoholism</institution></institution-wrap></funding-source><award-id>1R01AA025342</award-id><award-id>K08AA029182</award-id><principal-award-recipient><name name-style="western"><surname>McConnell</surname><given-names>Matthew J.</given-names></name><name name-style="western"><surname>Iwakiri</surname><given-names>Yasuko</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Alcohol-associated liver disease is a key driver of liver-related mortality in the USA [<xref ref-type="bibr" rid="CR1">1</xref>]. Alcoholic hepatitis (AH) is the severe, inflammatory manifestation of alcohol-associated liver disease. Recent data collected in a nationwide database from 2000 to 2011 suggest that patients with AH are becoming more severely ill with a higher median Model for End Stage Liver Disease (MELD) score and that these patients have an increasing number of comorbidities as well [<xref ref-type="bibr" rid="CR2">2</xref>]. More updated epidemiologic data from several states demonstrate an increase in incidence rate of AH among individuals in their 30&#160;s and 40&#160;s, with the highest overall rate in patients aged 40&#8211;59 [<xref ref-type="bibr" rid="CR3">3</xref>]. Additionally, patients with AH are having increasing numbers of complications which can be related to portal hypertension, including hepatic encephalopathy, ascites, hepatorenal syndrome, and gastrointestinal bleeding, presenting critical challenges for clinicians [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par5">This article aims to review the literature on portal hypertension in AH. Mechanisms of portal hypertension including alterations in portal inflow, changes in nitric oxide and vasoactive mediators, vascular lesions and fibrosis, and inflammation will be examined. The specific role of liver sinusoidal endothelial cells (LSECs) in portal hypertension in this disease will be discussed with respect to these various mechanisms. The article will conclude with an examination of the management of portal hypertension in AH. The diverse potential mechanisms mediating portal hypertension in AH are summarized in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Possible mechanisms of portal hypertension in alcohol-associated hepatitis: portal hypertension is likely multifactorial, with contributions from increased portal inflow as a direct effect of alcohol, increased intrahepatic vasoconstriction from decreased nitric oxide (NO) production as well as increased endothelin-1, systemic inflammation as well as inflammation within the liver, and increased perisinusoidal fibrosis and phlebosclerosis in the hepatic vasculature</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="11901_2023_601_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec2"><title>Portal Inflow and Portal Pressure</title><p id="Par6">Because AH occurs in the setting of ongoing alcohol intake, portal hypertension in this context may be due to the direct effects of alcohol on the portal circulation, which has been demonstrated in animal and human studies. Several studies have evaluated the effect of alcohol on portal pressure even in the absence of liver fibrosis or cirrhosis. In one animal study, acute oral ethanol intake was demonstrated to increase portal blood flow by 23&#8211;57% with increasing doses of ethanol (3.0 and 4.0&#160;g/kg), which was ameliorated by inhibition of alcohol dehydrogenase, suggesting a role of ethanol metabolism in this effect [<xref ref-type="bibr" rid="CR4">4</xref>]. Further work demonstrated that in the setting of partial portal vein ligation, ethanol ingestion increased not only portal tributary flow but also hepatic artery blood flow. This study also uncovered a role for adenosine signaling in the increased portal tributary blood flow in the portal vein ligation model following ethanol ingestion, finding that the added portal vein inflow in ethanol-fed, portal vein-ligated animals was inhibited by blocking adenosine signaling [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par7">In addition to animal studies, observations have been made in patients regarding the effects of alcohol on portal pressure, and possible mechanisms of alcohol-associated portal hypertension. Luca et. al. performed a study in which patients with alcohol-associated cirrhosis had their hepatic venous pressure gradient (HVPG) measured before and after consumption of identical beverages with and without ethanol. The authors found that ethanol intake increased HVPG and azygos blood flow, confirming that ethanol consumption directly places these patients at risk of portal hypertensive complications [<xref ref-type="bibr" rid="CR6">6</xref>]. This agrees with an earlier study noting that the histologic lesions characteristic of AH were associated with higher portal pressure than alcohol-associated cirrhosis alone [<xref ref-type="bibr" rid="CR7">7</xref>]. Another study of patients with chronic alcohol abuse but without cirrhosis or alcohol-associated hepatitis subjected to an intravenous ethanol infusion also demonstrated that ethanol alone can significantly increase portal pressure [<xref ref-type="bibr" rid="CR8">8</xref>]. In a more recent study in severe AH, HVPG was found to be a key prognostic indicator of survival, with a value less than or equal to 22&#160;mmHg predicting a 13% mortality, while a value greater than 22&#160;mmHg predicted a 66% mortality [<xref ref-type="bibr" rid="CR9">9</xref>]. In another study, the effect of alcohol consumption on portal pressure was assessed in follow-up after an episode of AH by comparing measurements of HVPG from during the episode of hepatitis with a subsequent measurement a median of 100&#160;days following the baseline measurement. Unsurprisingly, patients who achieved alcohol abstinence or reported only occasional drinking were more likely to have a greater than 20% reduction in HVPG on follow-up measurement than patients who exhibited harmful alcohol use [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec3"><title>Nitric Oxide and Other Vasoactive Signals</title><p id="Par8">Specific vasoactive mediators play a mechanistic role in the pathophysiology of portal hypertension in alcoholic hepatitis as well, with a key contribution by LSECs. Liver sinusoidal endothelial cells comprise nearly 90% of the liver endothelial cell (EC) population and play pivotal roles in liver homeostasis [<xref ref-type="bibr" rid="CR11">11</xref>] by regulating intrahepatic vascular tone and antigen clearance as well as maintaining functions of neighboring immune cells, hepatic stellate cells, and hepatocytes. LSEC dysfunction has been reported in alcohol-associated liver disease [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] and is thought to precede liver injury, and in general LSEC dysfunction is a key factor mediating portal hypertension in liver disease. Chronic alcohol intake decreases nitric oxide production in LSECs [<xref ref-type="bibr" rid="CR14">14</xref>], a hallmark of EC dysfunction, contributing to an increase in intrahepatic vascular resistance, given that nitric oxide is a key regulator of vascular tone.</p><p id="Par9">In addition to examining the role of ethanol in mediating portal inflow, a study in isolated perfused rat livers showed that ethanol infusion into the portal vein resulted in intrahepatic vasoconstriction and increased portal pressure, which was ameliorated by antagonism of endothelin-1 (a vasoconstrictor peptide synthesized by endothelial cells). When a nitric oxide synthesis inhibitor was infused into the portal vein along with ethanol, vasoconstriction due to ethanol was more sustained, implicating nitric oxide most likely derived from LSECs in this phenomenon as well [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par10">Another study of mechanisms of portal hypertension in AH examined patients with decompensated alcohol-associated cirrhosis alone or decompensated alcohol-associated cirrhosis with superimposed AH. The authors noted a significantly higher HVPG in the AH group and assessed whether the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) was increased in the AH group because inhibition of nitric oxide can raise portal pressure. The AH patients did in fact have higher plasma levels of ADMA, and the dimethylarginine score (ADMA plus its stereo-isomer SDMA) was a better predictor of survival than the MELD score and the Maddrey&#8217;s Discriminant Function [<xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec4"><title>Inflammation</title><p id="Par11">Translational studies examining the molecular phenomena accompanying portal hypertension in AH have identified several molecules associated with inflammation and vascular dysfunction as predictors and mediators of increased portal pressure. An early inflammatory mediator identified as responsible for portal hypertensive changes in AH was tumor necrosis factor &#945; (TNF-&#945;). In a key study, patients with severe AH were treated with the anti-TNF-&#945; antibody infliximab, and hemodynamic assessment was performed at baseline prior to treatment and repeated 24&#160;h following treatment, as well as prior to discharge in some patients. HVPG was significantly decreased 24&#160;h after treatment, and this decrease was sustained in the patients who agreed to the later hemodynamic assessment. This was accompanied by a decrease in other pro-inflammatory cytokines such as interleukin (IL)-6 and IL-8 as well [<xref ref-type="bibr" rid="CR17">17</xref>]. Unfortunately, despite this signal that portal pressure may be lowered by this treatment, anti-TNF-&#945; therapy was associated with increased 6-month mortality in AH in a randomized controlled trial and so is not currently recommended for clinical use in this setting [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par12">A study examining liver tissue from patients with AH compared with normal control livers demonstrated additional factors correlated with portal hypertension in AH. The median value for HVPG in the AH patients in this study was 20&#160;mmHg, and the authors found that expression of IL-8, C-X-C motif chemokine ligand (CXCL)1, and CXCL5 in the liver were significantly increased in patients with AH and HVPG&#8201;&gt;&#8201;20&#160;mmHg, suggesting a role for these inflammatory factors in the pathogenesis of portal hypertension in AH [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par13">An additional factor that seems to play a role in portal hypertension in AH is lipocalin 2 (LCN2). A study of patients with AH with advanced liver fibrosis and portal hypertension revealed that LCN2 expression in the liver was significantly correlated with HVPG as well as the expression of fibrogenic genes COL1A1 and TIMP1, suggesting this molecule plays a key pathogenic role in the progression of alcohol-associated liver disease. Interestingly, the upregulation of hepatic LCN2 was observed in AH but not other chronic liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatitis C(<xref ref-type="bibr" rid="CR20">20</xref>&#8226;).</p><p id="Par14">Turning to the intersection of inflammation and LSECs, endothelial hyperactivation is a form of EC dysfunction, most often referred to as an upregulation of genes involved in inflammation, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and CD146 (also known as melanoma cell adhesion molecule (MCAM) or cell surface glycoprotein MUC18). These cell adhesion molecules (CAMs) expressed on the surface of LSECs are thought to play a key role in adhesion of neutrophils, macrophages, and lymphocytes [<xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>] to LSECs before transmigration from circulation into the liver to induce hepatocyte injury. Inflammatory cytokines and growth factors induce upregulation of CAMs on ECs, thereby promoting inflammatory cell adhesion and trans-endothelial migration [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. As inflammation progresses, these CAMs on ECs can be cleaved from the cell surface and released into the blood as soluble forms. Studies have suggested that several soluble CAMs could be potential prognostic biomarkers and indicators of disease activity [<xref ref-type="bibr" rid="CR26">26</xref>&#8211;<xref ref-type="bibr" rid="CR28">28</xref>]. Soluble ICAM-1 and soluble VCAM-1 levels are elevated in patients with different liver diseases with excess alcohol ingestion, including AH and alcohol-associated cirrhosis [<xref ref-type="bibr" rid="CR29">29</xref>]. Elevated soluble CD146 levels are also observed in patients with cirrhosis due to alcohol, viral infection, or other etiologies, and could serve as a sensitive soluble marker to predict decompensation of cirrhosis [<xref ref-type="bibr" rid="CR30">30</xref>]. A recent study by Xia et al. [<xref ref-type="bibr" rid="CR31">31</xref>&#8226;] determined plasma levels of soluble CD146, soluble ICAM-1, and soluble VCAM-1 in patients with AH (<italic toggle="yes">n</italic>&#8201;=&#8201;79), heavy drinkers without clinical evidence of liver disease (HDC, <italic toggle="yes">n</italic>&#8201;=&#8201;66), then compared to those of healthy control (<italic toggle="yes">n</italic>&#8201;=&#8201;46). These soluble CAMs were also compared to their clinical parameters and plasma levels of inflammatory cytokines and growth factors that are related to EC activation and function. It was found that these soluble CAMs were highly elevated and related to disease severity of AH. In the HDC group, soluble VCAM-1 was the only CAM that showed a significant elevation compared to a healthy control group. Xia et al. [<xref ref-type="bibr" rid="CR31">31</xref>&#8226;] also determined whether alcohol abstinence could reduce EC hyperactivation in 31 AH patients and 30 HDC at 6-month follow-up as well as 18 AH patients and 25 HDC at 12-month follow-up after alcohol abstinence, and found that alcohol secession did not completely reverse these abnormalities.</p><p id="Par15">While CAMs are important for immune cell adhesion to the EC surface, multiple CXCL chemokines play a key role in the recruitment of inflammatory immune cells such as neutrophils. As discussed above, inflammatory cytokines such as TNF-&#945; are upregulated in AH and induce expression of CXCL1 and CXCL8 chemokines [<xref ref-type="bibr" rid="CR32">32</xref>], facilitating recruitment of neutrophils to the liver and leading to hepatotoxic injury and inflammation in AH [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. Liu et al. [<xref ref-type="bibr" rid="CR33">33</xref>] demonstrated the mechanism by which TNF-&#945; signaling leads to downstream transcriptional regulation in AH by characterizing transcriptomic and epigenomic changes in this disease. Several CXCL chemokines including CXCL1, 6, and 8 were found to be upregulated in the liver of AH patients as previously reported [<xref ref-type="bibr" rid="CR19">19</xref>]. As discussed above, several of these chemokines are also associated with HVPG&#8201;&gt;&#8201;20&#160;mmHg in patients with AH, suggesting a role in mediating portal hypertension. Further, the authors showed that the production of these CXCL chemokines is under the regulation of the TNF-&#945;/NFkB signaling axis via a &#8220;super-enhancer&#8221; region of the genome comprising multiple enhancers for an array of transcription factors, which regulate multiple target genes [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par16">The reticuloendothelial system in the liver refers to the system of phagocytosis and clearance of macromolecules and nanoparticles from the blood circulation, performed by activated Kupffer cells and LSECs. Overactivation of these reticuloendothelial cells in the sinusoids may correlate with disease severity and mortality in patients with severe AH. A prospective study was carried out in 50 severe AH patients (Maddrey&#8217;s discriminant function&#8201;&gt;&#8201;32 or MELD&#8201;&gt;&#8201;20) [<xref ref-type="bibr" rid="CR36">36</xref>]. Of these, 43 patients (82%) who fell into the category of very severe AH (Maddrey&#8217;s discriminant function, 76.23 (55.06&#8211;104.35)) showed a marked activation of the reticuloendothelial system with elevated levels of von Willebrand factor (vWF), an indicator of EC activation, as well as increased levels of soluble CD163 and ferritin, markers of macrophage activation. In addition, vWF was a predictor of mortality in severe AH. Given that 36 patients (72%) had systemic inflammatory syndrome and that these markers of macrophages and EC activation were measured in plasma, it is still possible that macrophages and ECs in tissues other than the liver may be contributing to these findings.</p><p id="Par17">Interleukin-6 is elevated in alcohol-associated liver disease [<xref ref-type="bibr" rid="CR17">17</xref>] and known as an indicator of systemic and tissue inflammation. Studies in mice showed that IL-6 is protective against alcohol-induced liver injury [<xref ref-type="bibr" rid="CR37">37</xref>]. Thus, it was speculated that the elevated IL-6 in alcohol-associated liver disease patients may play a compensatory role in protecting the liver from alcohol-induced liver injury. In general, IL-6 induces signaling through activation of signal transducer and activator of transcription 3 (STAT3) [<xref ref-type="bibr" rid="CR38">38</xref>]. In ECs, STAT3 has been thought of as anti-inflammatory and shown to protect against lipopolysaccharide (LPS)&#8211;induced inflammation [<xref ref-type="bibr" rid="CR39">39</xref>] and ischemia&#8211;reperfusion injury in the heart [<xref ref-type="bibr" rid="CR40">40</xref>]. Similarly, in LSECs, Gao et al. showed a protective role for STAT3 in ethanol-induced liver injury when endothelial-specific STAT3 knockout (KO) mice were given 4-week Lieber-DeCarli liquid diet containing 5% ethanol or control diet [<xref ref-type="bibr" rid="CR37">37</xref>]. In contrast to these protective roles of conventional IL-6 signaling, IL-6 trans-signaling in LSECs [<xref ref-type="bibr" rid="CR41">41</xref>], which is mediated by IL-6 and the soluble IL-6 receptor complex in the blood circulation, has been implicated in endotheliopathy and linked to liver injury in patients with COVID-19 [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Thus, activation of STAT3 might not be entirely anti-inflammatory, but may also have an opposing role depending on the activation pathway involved (conventional IL-6 vs. trans-signaling pathway).</p><p id="Par18">The role of infection in exacerbating portal hypertension in AH remains an area in which research is needed. In the landmark STOPAH trial, 12% of patients with severe AH presented with baseline infection [<xref ref-type="bibr" rid="CR44">44</xref>], and bacterial translocation is an important mechanism of worsening portal hypertension [<xref ref-type="bibr" rid="CR45">45</xref>]. However, studies on the precise role of infection in portal hypertension in alcohol-associated liver disease are currently lacking.</p></sec><sec id="Sec5"><title>Vascular Lesions and Fibrosis</title><p id="Par19">The effects of chronic alcohol consumption inducing liver fibrosis on portal hypertension have been evaluated in animal models. In one study in non-human primates, portal pressure in alcohol-fed animals was significantly correlated with perivenular fibrosis in the liver, suggesting a mechanistic role of this vascular lesion in portal hypertension [<xref ref-type="bibr" rid="CR46">46</xref>]. In a rat model of alcohol-induced liver fibrosis via chronic intragastric feeding, portal pressure was significantly raised and was associated with peri-sinusoidal fibrosis in the alcohol-fed animals, raising the possibility that this sinusoidal lesion is playing a key role in alcohol-induced portal hypertension [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par20">Additionally, several studies in patients have examined whether distinct vascular lesions in the liver may play a role in portal hypertension in AH. In one study by Goodman and Ishak, signs of portal hypertension in pre-cirrhotic AH were associated with the degree of veno-occlusive change and phlebosclerosis (perivenular scarring with gradual obliteration of the lumen of terminal hepatic venules) [<xref ref-type="bibr" rid="CR48">48</xref>]. Another study several years later by Burt and MacSween of patients with AH or alcohol-associated cirrhosis was less clear about the importance of veno-occlusive changes, but did note that phlebosclerosis was a universal finding and increased in severity with progressive degree of liver injury, again suggesting its importance in the progression of liver disease [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec><sec id="Sec6"><title>Management of Portal Hypertension in Alcoholic Hepatitis</title><p id="Par21">The general management of portal hypertensive complications in AH in the acute setting does not differ from other etiologies of portal hypertension and should adhere to best evidence and practice guidelines [<xref ref-type="bibr" rid="CR50">50</xref>&#8211;<xref ref-type="bibr" rid="CR52">52</xref>]. A specific consideration in AH is the effect of corticosteroid therapy on portal hypertension and its complications. In the foundational study by Maddrey et. al. on corticosteroid therapy in AH, there was no difference in decrease in portal pressure over 4&#160;weeks between the corticosteroid and placebo-treated groups [<xref ref-type="bibr" rid="CR53">53</xref>]. Clinicians often must consider whether to use corticosteroids in the situation of upper gastrointestinal bleeding in severe AH, and one study provides some guidance. Rudler et. al. retrospectively analyzed survival of severe AH patients treated with corticosteroids with or without upper GI bleeding (&gt;&#8201;50% with upper GI bleeding had variceal hemorrhage) and found no difference in survival between the two groups, suggesting that appropriately managed upper GI bleeding from portal hypertension is not an absolute contraindication to corticosteroid use [<xref ref-type="bibr" rid="CR54">54</xref>].</p><p id="Par22">Therapies to acutely ameliorate portal hypertension specifically in the setting of AH remain experimental. Lowering portal pressure in the setting of variceal hemorrhage should be carried out as per current guidelines with octreotide, non-selective beta blockers, and TIPS as indicated [<xref ref-type="bibr" rid="CR51">51</xref>]. One single-center, retrospective study has reported an association between non-selective beta blocker use in severe AH and acute kidney injury, but further data are needed before drawing broad conclusions regarding safety in this setting and as with all patients safe use requires attention to patient hemodynamics [<xref ref-type="bibr" rid="CR55">55</xref>]. While evidence on variceal hemorrhage specifically in AH remains sparse, one study evaluated outcomes of patients with AH undergoing emergency portacaval shunt surgery for bleeding esophageal varices and found no evidence that cirrhosis plus AH had a worse prognosis following surgery than cirrhosis alone [<xref ref-type="bibr" rid="CR56">56</xref>]. Another study evaluated TIPS placement for hepatorenal syndrome in a small number of patients with severe AH and found that TIPS improved creatinine, blood urea nitrogen, and urine output and may be an area of further study for renal portal hypertensive complications in these patients [<xref ref-type="bibr" rid="CR57">57</xref>]. An additional highly experimental study carried forward the findings that proinflammatory stimuli such as TNF-&#945; may be causing portal hypertension in AH and sought to ameliorate these changes with albumin dialysis. The authors found that patients receiving albumin dialysis had a significant reduction in HVPG versus those receiving hemofiltration alone, although the mechanism by which this occurred was unclear. This result suggests that albumin dialysis may be worthy of further study for acute lowering of portal hypertension in inflammatory conditions [<xref ref-type="bibr" rid="CR58">58</xref>].</p></sec><sec id="Sec7"><title>Conclusion</title><p id="Par23">Alcoholic hepatitis is a pressing clinical concern, and the impact of alcohol-associated liver disease in the USA is predicted to worsen due to the ongoing effects of the COVID-19 pandemic [<xref ref-type="bibr" rid="CR59">59</xref>]. Portal hypertension in AH is a key therapeutic target for mitigating complications, morbidity, and mortality from the disease. Future research concerning portal hypertension related to AH should address whether anti-inflammatory therapy can be directed to mitigate portal hypertension without adverse outcomes for patients, whether endothelium can be precisely targeted to prevent complications from portal hypertension in AH, and whether non-invasive markers of portal hypertension that can assist with prognosis and identifying patients who will benefit from future therapies in AH can be identified.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="funding-information"><title>Funding</title><p>NIH grants (R01DK117597, R01AA025342) to YI; NIH grants (K08AA029182) to MM.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par24">The authors have nothing to disclose.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref-list id="BSec1"><title>Papers of particular interest, published recently, have been highlighted as: &#8226; Of importance</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>ND</given-names></name></person-group><article-title>Mortality due to cirrhosis and liver cancer in the United States, 1999&#8211;2016: observational study</article-title><source>BMJ</source><year>2018</year><volume>362</volume><fpage>k2817</fpage><pub-id pub-id-type="doi">10.1136/bmj.k2817</pub-id><pub-id pub-id-type="pmid">30021785</pub-id><pub-id pub-id-type="pmcid">PMC6050518</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TA</given-names></name><name name-style="western"><surname>DeShazo</surname><given-names>JP</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>LR</given-names></name><name name-style="western"><surname>Puri</surname><given-names>P</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><article-title>The worsening profile of alcoholic hepatitis in the United States</article-title><source>Alcohol Clin Exp Res</source><year>2016</year><volume>40</volume><fpage>1295</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1111/acer.13069</pub-id><pub-id pub-id-type="pmid">27147285</pub-id><pub-id pub-id-type="pmcid">PMC4918810</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doshi</surname><given-names>SD</given-names></name><name name-style="western"><surname>Stotts</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hubbard</surname><given-names>RA</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>DS</given-names></name></person-group><article-title>The changing burden of alcoholic hepatitis: rising incidence and associations with age, gender, race, and geography</article-title><source>Dig Dis Sci</source><year>2021</year><volume>66</volume><fpage>1707</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1007/s10620-020-06346-8</pub-id><pub-id pub-id-type="pmid">32436122</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKaigney</surname><given-names>JP</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Saldivia</surname><given-names>V</given-names></name><name name-style="western"><surname>Israel</surname><given-names>Y</given-names></name><name name-style="western"><surname>Orrego</surname><given-names>H</given-names></name></person-group><article-title>Role of ethanol metabolism in the ethanol-induced increase in splanchnic circulation</article-title><source>Am J Physiol</source><year>1986</year><volume>250</volume><fpage>G518</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">3963196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajpgi.1986.250.4.G518</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma-Ansil</surname><given-names>B</given-names></name><name name-style="western"><surname>Carmichael</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Saldivia</surname><given-names>V</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>G</given-names></name><name name-style="western"><surname>Orrego</surname><given-names>H</given-names></name></person-group><article-title>Effect of ethanol on splanchnic hemodynamics in awake and unrestrained rats with portal hypertension</article-title><source>Hepatology</source><year>1989</year><volume>10</volume><fpage>946</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1002/hep.1840100609</pub-id><pub-id pub-id-type="pmid">2583689</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luca</surname><given-names>A</given-names></name><name name-style="western"><surname>Garcia-Pagan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name><name name-style="western"><surname>Feu</surname><given-names>F</given-names></name><name name-style="western"><surname>Caballeria</surname><given-names>J</given-names></name><name name-style="western"><surname>Groszmann</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Rodes</surname><given-names>J</given-names></name></person-group><article-title>Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis</article-title><source>Gastroenterology</source><year>1997</year><volume>112</volume><fpage>1284</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(97)70142-2</pub-id><pub-id pub-id-type="pmid">9098014</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poynard</surname><given-names>T</given-names></name><name name-style="western"><surname>Degott</surname><given-names>C</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>C</given-names></name><name name-style="western"><surname>Lebrec</surname><given-names>D</given-names></name></person-group><article-title>Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis Effect of acute alcoholic hepatitis on portal hypertension</article-title><source>Dig Dis Sci</source><year>1987</year><volume>32</volume><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1007/BF01296284</pub-id><pub-id pub-id-type="pmid">3829877</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>G</given-names></name><name name-style="western"><surname>Fluxa</surname><given-names>F</given-names></name><name name-style="western"><surname>Bresky</surname><given-names>G</given-names></name><name name-style="western"><surname>Backhouse</surname><given-names>C</given-names></name><name name-style="western"><surname>Palma</surname><given-names>M</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>S</given-names></name><etal/></person-group><article-title>Splanchnic and systemic hemodynamics in early abstinence and after ethanol administration in non-cirrhotic alcoholic patients</article-title><source>J Hepatol</source><year>1994</year><volume>20</volume><fpage>494</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(05)80496-9</pub-id><pub-id pub-id-type="pmid">8051388</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rincon</surname><given-names>D</given-names></name><name name-style="western"><surname>Lo Iacono</surname><given-names>O</given-names></name><name name-style="western"><surname>Ripoll</surname><given-names>C</given-names></name><name name-style="western"><surname>Gomez-Camarero</surname><given-names>J</given-names></name><name name-style="western"><surname>Salcedo</surname><given-names>M</given-names></name><name name-style="western"><surname>Catalina</surname><given-names>MV</given-names></name><name name-style="western"><surname>Hernando</surname><given-names>A</given-names></name><etal/></person-group><article-title>Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis</article-title><source>Aliment Pharmacol Ther</source><year>2007</year><volume>25</volume><fpage>841</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2007.03258.x</pub-id><pub-id pub-id-type="pmid">17373923</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Spahr L, Goossens N, Furrer F, Dupuis M, Vijgen S, Elkrief L, Giostra E, et al. A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis. Eur J Gastroenterol Hepatol 2018;30:967-974. <bold>This reference demonstrates the key role of treating alcohol use disorder and reducing harmful alcohol use in managing portal hypertension in alcohol-associated hepatitis.</bold><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0000000000001148</pub-id><pub-id pub-id-type="pmid">29727387</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lai</surname><given-names>S</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>M</given-names></name><name name-style="western"><surname>Utsumi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single-cell transcriptomics reveals zone-specific alterations of liver sinusoidal endothelial cells in cirrhosis</article-title><source>Cell Mol Gastroenterol Hepatol</source><year>2021</year><volume>11</volume><fpage>1139</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2020.12.007</pub-id><pub-id pub-id-type="pmid">33340713</pub-id><pub-id pub-id-type="pmcid">PMC7903131</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCuskey</surname><given-names>RS</given-names></name><name name-style="western"><surname>Bethea</surname><given-names>NW</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J</given-names></name><name name-style="western"><surname>McCuskey</surname><given-names>MK</given-names></name><name name-style="western"><surname>Abril</surname><given-names>ER</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Ito</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ethanol binging exacerbates sinusoidal endothelial and parenchymal injury elicited by acetaminophen</article-title><source>J Hepatol</source><year>2005</year><volume>42</volume><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2004.11.033</pub-id><pub-id pub-id-type="pmid">15710220</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nanji</surname><given-names>AA</given-names></name><name name-style="western"><surname>Tahan</surname><given-names>SR</given-names></name><name name-style="western"><surname>Khwaja</surname><given-names>S</given-names></name><name name-style="western"><surname>Yacoub</surname><given-names>LK</given-names></name><name name-style="western"><surname>Sadrzadeh</surname><given-names>SM</given-names></name></person-group><article-title>Elevated plasma levels of hyaluronic acid indicate endothelial cell dysfunction in the initial stages of alcoholic liver disease in the rat</article-title><source>J Hepatol</source><year>1996</year><volume>24</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(96)80018-3</pub-id><pub-id pub-id-type="pmid">8778206</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sangwung</surname><given-names>P</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>R</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y</given-names></name><name name-style="western"><surname>McConnell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J</given-names></name><name name-style="western"><surname>Utsumi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><fpage>377</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.02.028</pub-id><pub-id pub-id-type="pmid">33675874</pub-id><pub-id pub-id-type="pmcid">PMC8292196</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshita</surname><given-names>M</given-names></name><name name-style="western"><surname>Takei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawano</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoshihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Hijioka</surname><given-names>T</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>H</given-names></name><name name-style="western"><surname>Goto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Roles of endothelin-1 and nitric oxide in the mechanism for ethanol-induced vasoconstriction in rat liver</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><fpage>1337</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1172/JCI116334</pub-id><pub-id pub-id-type="pmid">8473486</pub-id><pub-id pub-id-type="pmcid">PMC288104</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mookerjee</surname><given-names>RP</given-names></name><name name-style="western"><surname>Malaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NA</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Dalton</surname><given-names>RN</given-names></name><name name-style="western"><surname>Turner</surname><given-names>C</given-names></name><name name-style="western"><surname>Sen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1002/hep.21491</pub-id><pub-id pub-id-type="pmid">17187433</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mookerjee</surname><given-names>RP</given-names></name><name name-style="western"><surname>Sen</surname><given-names>S</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NA</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name></person-group><article-title>Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis</article-title><source>Gut</source><year>2003</year><volume>52</volume><fpage>1182</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1136/gut.52.8.1182</pub-id><pub-id pub-id-type="pmid">12865279</pub-id><pub-id pub-id-type="pmcid">PMC1773767</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boetticher</surname><given-names>NC</given-names></name><name name-style="western"><surname>Peine</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Kwo</surname><given-names>P</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>GA</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T</given-names></name><name name-style="western"><surname>Aqel</surname><given-names>B</given-names></name><name name-style="western"><surname>Boardman</surname><given-names>L</given-names></name><etal/></person-group><article-title>A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.08.057</pub-id><pub-id pub-id-type="pmid">18848937</pub-id><pub-id pub-id-type="pmcid">PMC2639749</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez</surname><given-names>M</given-names></name><name name-style="western"><surname>Miquel</surname><given-names>R</given-names></name><name name-style="western"><surname>Colmenero</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>M</given-names></name><name name-style="western"><surname>Garcia-Pagan</surname><given-names>JC</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name><name name-style="western"><surname>Arroyo</surname><given-names>V</given-names></name><etal/></person-group><article-title>Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>1639</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.056</pub-id><pub-id pub-id-type="pmid">19208360</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Argemi</surname><given-names>J</given-names></name><name name-style="western"><surname>Odena</surname><given-names>G</given-names></name><name name-style="western"><surname>Xu</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Massey</surname><given-names>V</given-names></name><name name-style="western"><surname>Parrish</surname><given-names>A</given-names></name><etal/></person-group><article-title>Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>15558</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-72172-7</pub-id><pub-id pub-id-type="pmid">32968110</pub-id><pub-id pub-id-type="pmcid">PMC7512007</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bautista</surname><given-names>AP</given-names></name></person-group><article-title>Neutrophilic infiltration in alcoholic hepatitis</article-title><source>Alcohol</source><year>2002</year><volume>27</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/S0741-8329(02)00206-9</pub-id><pub-id pub-id-type="pmid">12062632</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haydon</surname><given-names>G</given-names></name><name name-style="western"><surname>Lalor</surname><given-names>PF</given-names></name><name name-style="western"><surname>Hubscher</surname><given-names>SG</given-names></name><name name-style="western"><surname>Adams</surname><given-names>DH</given-names></name></person-group><article-title>Lymphocyte recruitment to the liver in alcoholic liver disease</article-title><source>Alcohol</source><year>2002</year><volume>27</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/S0741-8329(02)00208-2</pub-id><pub-id pub-id-type="pmid">12062634</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sandahl</surname><given-names>TD</given-names></name><name name-style="western"><surname>Gronbaek</surname><given-names>H</given-names></name><name name-style="western"><surname>Moller</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Stoy</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>KL</given-names></name><name name-style="western"><surname>Dige</surname><given-names>AK</given-names></name><name name-style="western"><surname>Agnholt</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study</article-title><source>Am J Gastroenterol</source><year>2014</year><volume>109</volume><fpage>1749</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.262</pub-id><pub-id pub-id-type="pmid">25155228</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langer</surname><given-names>HF</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T</given-names></name></person-group><article-title>Leukocyte-endothelial interactions in inflammation</article-title><source>J Cell Mol Med</source><year>2009</year><volume>13</volume><fpage>1211</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00811.x</pub-id><pub-id pub-id-type="pmid">19538472</pub-id><pub-id pub-id-type="pmcid">PMC2861890</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaik-Dasthagirisaheb</surname><given-names>YB</given-names></name><name name-style="western"><surname>Varvara</surname><given-names>G</given-names></name><name name-style="western"><surname>Murmura</surname><given-names>G</given-names></name><name name-style="western"><surname>Saggini</surname><given-names>A</given-names></name><name name-style="western"><surname>Potalivo</surname><given-names>G</given-names></name><name name-style="western"><surname>Caraffa</surname><given-names>A</given-names></name><name name-style="western"><surname>Antinolfi</surname><given-names>P</given-names></name><etal/></person-group><article-title>Vascular endothelial growth factor (VEGF), mast cells and inflammation</article-title><source>Int J Immunopathol Pharmacol</source><year>2013</year><volume>26</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1177/039463201302600206</pub-id><pub-id pub-id-type="pmid">23755748</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothlein</surname><given-names>R</given-names></name><name name-style="western"><surname>Mainolfi</surname><given-names>EA</given-names></name><name name-style="western"><surname>Czajkowski</surname><given-names>M</given-names></name><name name-style="western"><surname>Marlin</surname><given-names>SD</given-names></name></person-group><article-title>A form of circulating ICAM-1 in human serum</article-title><source>J Immunol</source><year>1991</year><volume>147</volume><fpage>3788</fpage><lpage>3793</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.147.11.3788</pub-id><pub-id pub-id-type="pmid">1682385</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasseville</surname><given-names>VG</given-names></name><name name-style="western"><surname>Newman</surname><given-names>WA</given-names></name><name name-style="western"><surname>Lackner</surname><given-names>AA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>MO</given-names></name><name name-style="western"><surname>Lausen</surname><given-names>NC</given-names></name><name name-style="western"><surname>Beall</surname><given-names>D</given-names></name><name name-style="western"><surname>Ringler</surname><given-names>DJ</given-names></name></person-group><article-title>Elevated vascular cell adhesion molecule-1 in AIDS encephalitis induced by simian immunodeficiency virus</article-title><source>Am J Pathol</source><year>1992</year><volume>141</volume><fpage>1021</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">1279978</pub-id><pub-id pub-id-type="pmcid">PMC1886675</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>AR</given-names></name><name name-style="western"><surname>Anderstam</surname><given-names>B</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>M</given-names></name><name name-style="western"><surname>Heimburger</surname><given-names>O</given-names></name><name name-style="western"><surname>Barany</surname><given-names>P</given-names></name><etal/></person-group><article-title>Circulating vascular endothelial growth factor (VEGF) and its soluble receptor 1 (sVEGFR-1) are associated with inflammation and mortality in incident dialysis patients</article-title><source>Nephrol Dial Transplant</source><year>2013</year><volume>28</volume><fpage>2356</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.1093/ndt/gft256</pub-id><pub-id pub-id-type="pmid">23828162</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>DH</given-names></name><name name-style="western"><surname>Burra</surname><given-names>P</given-names></name><name name-style="western"><surname>Hubscher</surname><given-names>SG</given-names></name><name name-style="western"><surname>Elias</surname><given-names>E</given-names></name><name name-style="western"><surname>Newman</surname><given-names>W</given-names></name></person-group><article-title>Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease</article-title><source>Hepatology</source><year>1994</year><volume>19</volume><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1002/hep.1840190308</pub-id><pub-id pub-id-type="pmid">7509770</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nomikou</surname><given-names>E</given-names></name><name name-style="western"><surname>Alexopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Vasilieva</surname><given-names>L</given-names></name><name name-style="western"><surname>Agiasotelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Pavlou</surname><given-names>E</given-names></name><name name-style="western"><surname>Theodossiades</surname><given-names>G</given-names></name><name name-style="western"><surname>Dourakis</surname><given-names>SP</given-names></name></person-group><article-title>Soluble CD146, a novel endothelial marker, is related to the severity of liver disease</article-title><source>Scand J Gastroenterol</source><year>2015</year><volume>50</volume><fpage>577</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.3109/00365521.2014.985706</pub-id><pub-id pub-id-type="pmid">25636502</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VH</given-names></name><name name-style="western"><surname>Chalasani</surname><given-names>NP</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Persistent hyperactivation of endothelial cells in patients with alcoholic hepatitis</article-title><source>Alcohol Clin Exp Res</source><year>2020</year><volume>44</volume><fpage>1075</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1111/acer.14331</pub-id><pub-id pub-id-type="pmid">32246771</pub-id><pub-id pub-id-type="pmcid">PMC7255105</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>MF</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>LE</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>H</given-names></name></person-group><article-title>Inflammatory pathways in alcoholic steatohepatitis</article-title><source>J Hepatol</source><year>2019</year><volume>70</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.10.023</pub-id><pub-id pub-id-type="pmid">30658726</pub-id><pub-id pub-id-type="pmcid">PMC6361545</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>4560</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24843-w</pub-id><pub-id pub-id-type="pmid">34315876</pub-id><pub-id pub-id-type="pmcid">PMC8316465</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathurin</surname><given-names>P</given-names></name><name name-style="western"><surname>Mendenhall</surname><given-names>CL</given-names></name><name name-style="western"><surname>Carithers</surname><given-names>RL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Ramond</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Maddrey</surname><given-names>WC</given-names></name><name name-style="western"><surname>Garstide</surname><given-names>P</given-names></name><name name-style="western"><surname>Rueff</surname><given-names>B</given-names></name><etal/></person-group><article-title>Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH</article-title><source>J Hepatol</source><year>2002</year><volume>36</volume><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(01)00289-6</pub-id><pub-id pub-id-type="pmid">11943418</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sehrawat</surname><given-names>TS</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VH</given-names></name></person-group><article-title>The knowns and unknowns of treatment for alcoholic hepatitis</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><fpage>494</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(19)30326-7</pub-id><pub-id pub-id-type="pmid">32277902</pub-id><pub-id pub-id-type="pmcid">PMC7238289</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vijayalekshmi</surname><given-names>B</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>SB</given-names></name><name name-style="western"><surname>Nair</surname><given-names>SC</given-names></name><name name-style="western"><surname>Mammen</surname><given-names>J</given-names></name><name name-style="western"><surname>Goel</surname><given-names>A</given-names></name><name name-style="western"><surname>Zachariah</surname><given-names>UG</given-names></name><etal/></person-group><article-title>Reticuloendothelial activation correlates with disease severity and predicts mortality in severe alcoholic hepatitis</article-title><source>Eur J Gastroenterol Hepatol</source><year>2021</year><volume>33</volume><fpage>e329</fpage><lpage>e334</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000002056</pub-id><pub-id pub-id-type="pmid">33470708</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Park</surname><given-names>O</given-names></name><name name-style="western"><surname>Horiguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Lafdil</surname><given-names>F</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>P</given-names></name><name name-style="western"><surname>Moh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Anti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury</article-title><source>Alcohol Clin Exp Res</source><year>2010</year><volume>34</volume><fpage>719</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.2009.01141.x</pub-id><pub-id pub-id-type="pmid">20102572</pub-id><pub-id pub-id-type="pmcid">PMC2858250</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wegenka</surname><given-names>UM</given-names></name><name name-style="western"><surname>Buschmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Lutticken</surname><given-names>C</given-names></name><name name-style="western"><surname>Heinrich</surname><given-names>PC</given-names></name><name name-style="western"><surname>Horn</surname><given-names>F</given-names></name></person-group><article-title>Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level</article-title><source>Mol Cell Biol</source><year>1993</year><volume>13</volume><fpage>276</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">7678052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mcb.13.1.276</pub-id><pub-id pub-id-type="pmcid">PMC358907</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kano</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolfgang</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jacoby</surname><given-names>J</given-names></name><name name-style="western"><surname>Chai</surname><given-names>GX</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>W</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Endothelial cells require STAT3 for protection against endotoxin-induced inflammation</article-title><source>J Exp Med</source><year>2003</year><volume>198</volume><fpage>1517</fpage><lpage>1525</lpage><pub-id pub-id-type="doi">10.1084/jem.20030077</pub-id><pub-id pub-id-type="pmid">14623907</pub-id><pub-id pub-id-type="pmcid">PMC2194113</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Crisostomo</surname><given-names>P</given-names></name><name name-style="western"><surname>Markel</surname><given-names>T</given-names></name><name name-style="western"><surname>Meldrum</surname><given-names>KK</given-names></name><name name-style="western"><surname>Fu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Meldrum</surname><given-names>DR</given-names></name></person-group><article-title>Endothelial STAT3 plays a critical role in generalized myocardial proinflammatory and proapoptotic signaling</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2007</year><volume>293</volume><fpage>H2101</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00125.2007</pub-id><pub-id pub-id-type="pmid">17675575</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rose-John</surname><given-names>S</given-names></name><name name-style="western"><surname>Heinrich</surname><given-names>PC</given-names></name></person-group><article-title>Soluble receptors for cytokines and growth factors: generation and biological function</article-title><source>Biochem J</source><year>1994</year><volume>300</volume><issue>Pt 2</issue><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1042/bj3000281</pub-id><pub-id pub-id-type="pmid">8002928</pub-id><pub-id pub-id-type="pmcid">PMC1138158</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McConnell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>R</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Iwakiri</surname><given-names>Y</given-names></name></person-group><article-title>Covid-19 and liver injury: role of inflammatory endotheliopathy, platelet dysfunction, and thrombosis</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><fpage>255</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1002/hep4.1843</pub-id><pub-id pub-id-type="pmid">34658172</pub-id><pub-id pub-id-type="pmcid">PMC8652692</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McConnell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>R</given-names></name><name name-style="western"><surname>Sonzogni</surname><given-names>A</given-names></name><name name-style="western"><surname>Licini</surname><given-names>L</given-names></name><name name-style="western"><surname>Valle</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonaffini</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2021.04.050</pub-id><pub-id pub-id-type="pmid">33991637</pub-id><pub-id pub-id-type="pmcid">PMC8285256</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Thursz MR, Forrest EH, Ryder S, investigators S. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;373:282&#8211;283.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1506342</pub-id><pub-id pub-id-type="pmid">26176387</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><name name-style="western"><surname>Martin-Mateos</surname><given-names>RM</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VH</given-names></name></person-group><article-title>Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg</article-title><source>Hepatol Int</source><year>2018</year><volume>12</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s12072-017-9798-x</pub-id><pub-id pub-id-type="pmid">28550391</pub-id><pub-id pub-id-type="pmcid">PMC6876989</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyakawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Iida</surname><given-names>S</given-names></name><name name-style="western"><surname>Leo</surname><given-names>MA</given-names></name><name name-style="western"><surname>Greenstein</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Zimmon</surname><given-names>DS</given-names></name><name name-style="western"><surname>Lieber</surname><given-names>CS</given-names></name></person-group><article-title>Pathogenesis of precirrhotic portal hypertension in alcohol-fed baboons</article-title><source>Gastroenterology</source><year>1985</year><volume>88</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(85)80146-3</pub-id><pub-id pub-id-type="pmid">3964762</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Niu</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JF</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tao</surname><given-names>XH</given-names></name></person-group><article-title>Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>6483</fpage><lpage>6488</lpage><pub-id pub-id-type="doi">10.3748/wjg.v11.i41.6483</pub-id><pub-id pub-id-type="pmid">16425420</pub-id><pub-id pub-id-type="pmcid">PMC4355790</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodman</surname><given-names>ZD</given-names></name><name name-style="western"><surname>Ishak</surname><given-names>KG</given-names></name></person-group><article-title>Occlusive venous lesions in alcoholic liver disease A study of 200 cases</article-title><source>Gastroenterology</source><year>1982</year><volume>83</volume><fpage>786</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(82)80007-3</pub-id><pub-id pub-id-type="pmid">7106509</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burt</surname><given-names>AD</given-names></name><name name-style="western"><surname>MacSween</surname><given-names>RN</given-names></name></person-group><article-title>Hepatic vein lesions in alcoholic liver disease: retrospective biopsy and necropsy study</article-title><source>J Clin Pathol</source><year>1986</year><volume>39</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1136/jcp.39.1.63</pub-id><pub-id pub-id-type="pmid">3950032</pub-id><pub-id pub-id-type="pmcid">PMC499614</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crabb</surname><given-names>DW</given-names></name><name name-style="western"><surname>Im</surname><given-names>GY</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>G</given-names></name><name name-style="western"><surname>Mellinger</surname><given-names>JL</given-names></name><name name-style="western"><surname>Lucey</surname><given-names>MR</given-names></name></person-group><article-title>Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2020</year><volume>71</volume><fpage>306</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1002/hep.30866</pub-id><pub-id pub-id-type="pmid">31314133</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name name-style="western"><surname>Abraldes</surname><given-names>JG</given-names></name><name name-style="western"><surname>Berzigotti</surname><given-names>A</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name></person-group><article-title>Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases</article-title><source>Hepatology</source><year>2017</year><volume>65</volume><fpage>310</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1002/hep.28906</pub-id><pub-id pub-id-type="pmid">27786365</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biggins</surname><given-names>SW</given-names></name><name name-style="western"><surname>Angeli</surname><given-names>P</given-names></name><name name-style="western"><surname>Garcia-Tsao</surname><given-names>G</given-names></name><name name-style="western"><surname>Gines</surname><given-names>P</given-names></name><name name-style="western"><surname>Ling</surname><given-names>SC</given-names></name><name name-style="western"><surname>Nadim</surname><given-names>MK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>F</given-names></name><etal/></person-group><article-title>Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>1014</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1002/hep.31884</pub-id><pub-id pub-id-type="pmid">33942342</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddrey</surname><given-names>WC</given-names></name><name name-style="western"><surname>Boitnott</surname><given-names>JK</given-names></name><name name-style="western"><surname>Bedine</surname><given-names>MS</given-names></name><name name-style="western"><surname>Weber</surname><given-names>FL</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Mezey</surname><given-names>E</given-names></name><name name-style="western"><surname>White</surname><given-names>RI</given-names><suffix>Jr</suffix></name></person-group><article-title>Corticosteroid therapy of alcoholic hepatitis</article-title><source>Gastroenterology</source><year>1978</year><volume>75</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(78)90401-8</pub-id><pub-id pub-id-type="pmid">352788</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudler</surname><given-names>M</given-names></name><name name-style="western"><surname>Mouri</surname><given-names>S</given-names></name><name name-style="western"><surname>Charlotte</surname><given-names>F</given-names></name><name name-style="western"><surname>Lebray</surname><given-names>P</given-names></name><name name-style="western"><surname>Capocci</surname><given-names>R</given-names></name><name name-style="western"><surname>Benosman</surname><given-names>H</given-names></name><name name-style="western"><surname>Poynard</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prognosis of treated severe alcoholic hepatitis in patients with gastrointestinal bleeding</article-title><source>J Hepatol</source><year>2015</year><volume>62</volume><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.11.003</pub-id><pub-id pub-id-type="pmid">25450199</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serste</surname><given-names>T</given-names></name><name name-style="western"><surname>Njimi</surname><given-names>H</given-names></name><name name-style="western"><surname>Degre</surname><given-names>D</given-names></name><name name-style="western"><surname>Deltenre</surname><given-names>P</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>J</given-names></name><name name-style="western"><surname>Lepida</surname><given-names>A</given-names></name><name name-style="western"><surname>Trepo</surname><given-names>E</given-names></name><etal/></person-group><article-title>The use of beta-blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis</article-title><source>Liver Int</source><year>2015</year><volume>35</volume><fpage>1974</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1111/liv.12786</pub-id><pub-id pub-id-type="pmid">25611961</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>RH</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Miyai</surname><given-names>K</given-names></name><name name-style="western"><surname>Orloff</surname><given-names>MJ</given-names></name></person-group><article-title>Outcome in cirrhotic patients with acute alcoholic hepatitis after emergency portacaval shunt for bleeding esophageal varices</article-title><source>Am J Surg</source><year>1984</year><volume>147</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/0002-9610(84)90038-2</pub-id><pub-id pub-id-type="pmid">6606990</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Testino</surname><given-names>G</given-names></name><name name-style="western"><surname>Leone</surname><given-names>S</given-names></name><name name-style="western"><surname>Ferro</surname><given-names>C</given-names></name><name name-style="western"><surname>Borro</surname><given-names>P</given-names></name></person-group><article-title>Severe acute alcoholic hepatitis and hepatorenal syndrome: role of transjugular intrahepatic portosystemic stent shunt</article-title><source>J Med Life</source><year>2012</year><volume>5</volume><fpage>203</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">22802893</pub-id><pub-id pub-id-type="pmcid">PMC3391868</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sen</surname><given-names>S</given-names></name><name name-style="western"><surname>Mookerjee</surname><given-names>RP</given-names></name><name name-style="western"><surname>Cheshire</surname><given-names>LM</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name></person-group><article-title>Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis</article-title><source>J Hepatol</source><year>2005</year><volume>43</volume><fpage>142</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2005.01.032</pub-id><pub-id pub-id-type="pmid">15878216</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Julien</surname><given-names>J</given-names></name><name name-style="western"><surname>Ayer</surname><given-names>T</given-names></name><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>C</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>WN</given-names></name><name name-style="western"><surname>Chhatwal</surname><given-names>J</given-names></name></person-group><article-title>Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study</article-title><source>Hepatology</source><year>2022</year><volume>75</volume><fpage>1480</fpage><lpage>1490</lpage><pub-id pub-id-type="doi">10.1002/hep.32272</pub-id><pub-id pub-id-type="pmid">34878683</pub-id><pub-id pub-id-type="pmcid">PMC9015640</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jinjuvadia</surname><given-names>R</given-names></name><name name-style="western"><surname>Liangpunsakul</surname><given-names>S</given-names></name><name name-style="western"><surname>Translational</surname><given-names>R</given-names></name></person-group><article-title>Evolving alcoholic hepatitis treatment C. Trends in alcoholic hepatitis-related hospitalizations, financial burden, and mortality in the United States</article-title><source>J Clin Gastroenterol</source><year>2015</year><volume>49</volume><fpage>506</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1097/MCG.0000000000000161</pub-id><pub-id pub-id-type="pmid">25198164</pub-id><pub-id pub-id-type="pmcid">PMC4276725</pub-id></element-citation></ref></ref-list></ref-list></back></article></pmc-articleset>